Head to Head Review: Semler Scientific (OTCMKTS:SMLR) versus CONMED (OTCMKTS:CNMD)

Semler Scientific (OTCMKTS:SMLR) and CONMED (NASDAQ:CNMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional & Insider Ownership

12.0% of Semler Scientific shares are owned by institutional investors. Comparatively, 96.8% of CONMED shares are owned by institutional investors. 13.9% of Semler Scientific shares are owned by company insiders. Comparatively, 4.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dividends

CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 0.9%. Semler Scientific does not pay a dividend. CONMED pays out 36.7% of its earnings in the form of a dividend.

Analyst Ratings

This is a summary of current ratings and price targets for Semler Scientific and CONMED, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semler Scientific 0 0 2 0 3.00
CONMED 0 1 3 0 2.75

Semler Scientific presently has a consensus target price of $44.00, suggesting a potential upside of 0.23%. CONMED has a consensus target price of $90.50, suggesting a potential upside of 4.09%. Given CONMED’s higher probable upside, analysts clearly believe CONMED is more favorable than Semler Scientific.

Volatility & Risk

Semler Scientific has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, CONMED has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Profitability

This table compares Semler Scientific and CONMED’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Semler Scientific 25.90% 191.41% 84.63%
CONMED 3.56% 9.67% 4.38%

Valuation and Earnings

This table compares Semler Scientific and CONMED’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Semler Scientific $21.49 million 13.19 $5.01 million $0.66 66.52
CONMED $859.63 million 2.86 $40.85 million $2.18 39.88

CONMED has higher revenue and earnings than Semler Scientific. CONMED is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Semler Scientific Company Profile

Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and VCARE uterine manipulator for enhancing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit